Pacific Biosciences Of California (PACB) Operating Expenses (2010 - 2026)

Pacific Biosciences Of California has reported Operating Expenses for 17 years, with the latest figure at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 95.04% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $193.3 million (down 77.17% YoY), and the FY2025 full-year result was $599.6 million, up 17.21% from the prior year.
• Operating Expenses for Q1 2026 stood at $21.2 million, down from $57.8 million in the prior quarter.
• The five-year high for Operating Expenses was $427.6 million in Q1 2025, with the low at $21.2 million in Q1 2026.
• Average Operating Expenses over 5 years is $110.3 million, with a median of $91.7 million recorded in 2022.
• Year-over-year, Operating Expenses soared 634.72% in 2022 and slumped 95.04% in 2026.
• Tracing PACB's Operating Expenses over 5 years: stood at $92.2 million in 2022, then climbed by 5.31% to $97.1 million in 2023, then surged by 67.92% to $163.1 million in 2024, then slumped by 64.58% to $57.8 million in 2025, then plunged by 63.3% to $21.2 million in 2026.
• The last three Operating Expenses figures came in at $21.2 million (Q1 2026), $57.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.

Peer Comparison